Novo Nordisk A/S Stock Price, News & Analysis (NYSE:NVO)

$57.79 1.28 (2.27 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$57.79
Today's Range$57.35 - $57.82
52-Week Range$32.83 - $57.82
Volume2.09 million shs
Average Volume638,358 shs
Market Capitalization$147.36 billion
P/E Ratio25.24
Dividend Yield1.41%
Beta0.63

About Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S logoNovo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVO
CUSIPN/A
Phone45-4444-8888

Debt

Debt-to-Equity RatioN/A
Current Ratio1.27%
Quick Ratio0.93%

Price-To-Earnings

Trailing P/E Ratio25.2359180607776
Forward P/E Ratio23.68
P/E Growth3.02

Sales & Book Value

Annual Sales$15.98 billion
Price / Sales9.22
Cash Flow$2.33 per share
Price / Cash24.78
Book Value$2.66 per share
Price / Book21.73

Profitability

Trailing EPS$2.29
Net Income$5.64 billion
Net Margins34.11%
Return on Equity84.64%
Return on Assets39.57%

Miscellaneous

Employees41,971
Outstanding Shares2,550,000,000

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced an annual dividend on Wednesday, August 9th. Stockholders of record on Monday, August 21st will be paid a dividend of $0.336 per share on Tuesday, August 29th. This represents a dividend yield of 1.07%. The ex-dividend date of this dividend is Friday, August 18th. This is a positive change from Novo Nordisk A/S's previous annual dividend of $0.33. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its board has authorized a share repurchase plan on Thursday, April 6th 2017, which authorizes the company to repurchase outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 18.9% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings data on Wednesday, November, 1st. The company reported $0.62 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.58 by $0.04. Novo Nordisk A/S had a net margin of 34.11% and a return on equity of 84.64%. View Novo Nordisk A/S's Earnings History.

When will Novo Nordisk A/S make its next earnings announcement?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Novo Nordisk A/S.

Who are some of Novo Nordisk A/S's key competitors?

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:

  • Goran A. Ando M.D., Chairman of the Board (Age 68)
  • Lars Fruergaard Joergensen, President, Chief Executive Officer (Age 50)
  • Jeppe Christiansen, Vice Chairman of the Board (Age 58)
  • Jesper Brandgaard, Chief Financial Officer, Executive Vice President (Age 54)
  • Maziar Mike Doustdar, Executive Vice President, International Operations (Age 46)
  • Mads Krogsgaard Thomsen, Chief Science Officer, Executive Vice President (Age 56)
  • Doug Langa, Executive Vice President, North America Operations
  • Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate Affairs
  • Henrik Ehlers Wulff, Executive Vice President, Product Supply (Age 47)
  • Liselotte Hyveled, Director, Employee Representative (Age 51)

Who owns Novo Nordisk A/S stock?

Novo Nordisk A/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Saratoga Research & Investment Management (0.06%), Alta Capital Management LLC (0.03%), Raub Brock Capital Management LP (0.01%), Bank of Montreal Can (0.00%), Clean Yield Group (0.00%) and Smithbridge Asset Management Inc. DE (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

Who sold Novo Nordisk A/S stock? Who is selling Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was sold by a variety of institutional investors in the last quarter, including Raub Brock Capital Management LP, Alta Capital Management LLC, Bartlett & Co. LLC, Bank of Montreal Can, Wendell David Associates Inc. and Clean Yield Group. View Insider Buying and Selling for Novo Nordisk A/S.

Who bought Novo Nordisk A/S stock? Who is buying Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was purchased by a variety of institutional investors in the last quarter, including Saratoga Research & Investment Management, KCS Wealth Advisory, TRUE Private Wealth Advisors, Creative Planning, Atria Investments LLC, Charter Trust Co., Addenda Capital Inc. and Smithbridge Asset Management Inc. DE. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy Novo Nordisk A/S stock?

Shares of Novo Nordisk A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of Novo Nordisk A/S stock can currently be purchased for approximately $57.79.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $147.36 billion and generates $15.98 billion in revenue each year. The company earns $5.64 billion in net income (profit) each year or $2.29 on an earnings per share basis. Novo Nordisk A/S employs 41,971 workers across the globe.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NVO)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novo Nordisk A/S (NYSE:NVO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.001.752.00
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$57.00
Price Target Upside: N/AN/AN/A68.04% upside

Novo Nordisk A/S (NYSE:NVO) Consensus Price Target History

Price Target History for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2018Deutsche BankReiterated RatingBuyLowView Rating Details
12/29/2017JPMorgan Chase & Co.UpgradeUnderweight -> NeutralLowView Rating Details
12/6/2017Bank of AmericaUpgradeNeutral -> BuyMediumView Rating Details
12/1/2017Morgan StanleyUpgradeEqual Weight -> OverweightMediumView Rating Details
9/25/2017BNP ParibasDowngradeOutperform -> NeutralHighView Rating Details
3/7/2017BarclaysInitiated CoverageUnderweightN/AView Rating Details
12/20/2016Jefferies GroupReiterated RatingHoldN/AView Rating Details
12/1/2016Credit Suisse GroupReiterated RatingHoldN/AView Rating Details
10/31/2016DNB MarketsDowngradeBuy -> HoldN/AView Rating Details
10/31/2016CitigroupDowngradeBuy -> NeutralN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/13/2016Pacific CrestUpgradeNeutral -> OutperformN/AView Rating Details
6/28/2016Goldman Sachs GroupDowngradeConviction-Buy -> BuyN/AView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Novo Nordisk A/S (NYSE:NVO) Earnings History and Estimates Chart

Earnings by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE NVO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018$0.56N/AView Earnings Details
11/1/2017Q3 2017$0.58$0.62ViewN/AView Earnings Details
8/10/2017Q2 2017$0.56$0.59ViewN/AView Earnings Details
5/3/2017Q1 2017$0.53$0.58ViewN/AView Earnings Details
2/2/2017Q4 2016$0.52$0.50ViewN/AView Earnings Details
10/28/2016Q3 2016$0.56$0.58ViewN/AView Earnings Details
8/5/2016Q2 2016$0.58$0.60ViewN/AView Earnings Details
4/29/2016Q1$0.53$0.55$4.07 billion$4.02 billionViewListenView Earnings Details
2/3/2016Q4 2015$0.48$0.47ViewN/AView Earnings Details
10/29/2015Q3$0.47$0.49$4.03 billion$3.99 billionViewN/AView Earnings Details
8/6/2015Q2 2015$0.48ViewN/AView Earnings Details
4/30/2015Q1$0.39$0.45$25.13 billion$25.20 billionViewN/AView Earnings Details
1/30/2015Q4$2.48$0.38$24.67 billion$24.59 billionViewN/AView Earnings Details
10/30/2014Q3 2014$0.42ViewN/AView Earnings Details
8/7/2014Q2$2.60$0.48$21.86 billion$21.63 billionViewN/AView Earnings Details
5/1/2014Q1$0.44$0.45$20.83 billion$20.30 billionViewN/AView Earnings Details
1/28/2014Q413$0.42ViewN/AView Earnings Details
10/31/2013Q1$12.11$2.20$21.04 billion$20.51 billionViewN/AView Earnings Details
8/8/2013Q1$11.97$12.45$21.09 billion$21.38 billionViewN/AView Earnings Details
5/1/2013$10.67$10.98$19.73 billion$19.98 billionViewN/AView Earnings Details
1/31/2013$9.77$10.53$20.83 billion$20.96 billionViewN/AView Earnings Details
10/31/2012Q312$9.43$10.33$57.10 millionViewN/AView Earnings Details
8/9/2012Q2 2012$0.32ViewN/AView Earnings Details
4/27/2012Q1 2012$0.30ViewN/AView Earnings Details
2/2/2012Q4 2011$0.26$0.30ViewN/AView Earnings Details
10/27/2011Q3 2011$0.27$0.28ViewN/AView Earnings Details
8/4/2011Q2 2011$0.29$0.28ViewN/AView Earnings Details
2/2/2011Q4 2010$0.27$0.25ViewN/AView Earnings Details
10/27/2010Q3 2010$0.23ViewN/AView Earnings Details
8/19/2010Q2 2010$0.19$0.21ViewN/AView Earnings Details
4/30/2010Q1 2009$0.16ViewN/AView Earnings Details
2/2/2010Q4 2009$0.16ViewN/AView Earnings Details
10/29/2009Q3 2009$0.18ViewN/AView Earnings Details
1/29/2009Q4 2008$0.13ViewN/AView Earnings Details
10/30/2008Q3 2008$0.17ViewN/AView Earnings Details
4/30/2008Q1 2008$0.14ViewN/AView Earnings Details
1/31/2008Q4 2007$0.06ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Novo Nordisk A/S (NYSE:NVO) Earnings Estimates

Current Year EPS Consensus Estimate: $2.44 EPS
Next Year EPS Consensus Estimate: $2.56 EPS

Dividends

Novo Nordisk A/S (NYSE:NVO) Dividend Information

Most Recent Dividend:8/29/2017
Annual Dividend:$0.82
Dividend Yield:1.42%
Dividend Growth:10.40% (3 Year Average)
Payout Ratio:35.81% (Trailing 12 Months of Earnings)
33.61% (Based on This Year's Estimates)
32.03% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/9/2017annual$0.341.07%8/18/20178/21/20178/29/2017
2/7/2017annual$0.661.99%3/23/20173/27/20174/4/2017
8/8/2016$0.338/11/20168/15/20168/23/2016
2/16/2016Annual$0.703/18/20163/22/20163/30/2016
3/17/2014annual$0.841.83%3/21/20143/25/20144/2/2014
2/27/2013annual$3.181.81%3/21/20133/25/20134/2/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novo Nordisk A/S (NYSE NVO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 6.17%
Insider Trades by Quarter for Novo Nordisk A/S (NYSE:NVO)
Insider Trades by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE NVO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2017Eric S SprottInsiderBuy50,000$8.34$417,000.00
2/18/2015Richmond Partners Master LimitInsiderSell24,900$1.28$31,876.98
(Data available from 1/1/2013 forward)

Headlines

Novo Nordisk A/S (NYSE NVO) News Headlines

Source:
DateHeadline
Financial Survey: Novo Nordisk A/S (NVO) versus Aceto (ACET)Financial Survey: Novo Nordisk A/S (NVO) versus Aceto (ACET)
www.americanbankingnews.com - January 20 at 1:10 AM
Novo Nordisk A/S (NVO) Upgraded to Conviction-Buy by Goldman Sachs GroupNovo Nordisk A/S (NVO) Upgraded to Conviction-Buy by Goldman Sachs Group
www.americanbankingnews.com - January 19 at 9:25 AM
Jefferies Group Weighs in on Novo Nordisk A/Ss FY2022 Earnings (NVO)Jefferies Group Weighs in on Novo Nordisk A/S's FY2022 Earnings (NVO)
www.americanbankingnews.com - January 18 at 11:32 PM
Novo Nordisk A/S (NVO) Downgraded by Zacks Investment Research to "Hold"Novo Nordisk A/S (NVO) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 18 at 12:10 PM
FY2017 Earnings Estimate for Novo Nordisk A/S Issued By Jefferies Group (NVO)FY2017 Earnings Estimate for Novo Nordisk A/S Issued By Jefferies Group (NVO)
www.americanbankingnews.com - January 18 at 6:44 AM
Novo Nordisks (NVO) Hits 52-Week High: Whats Driving It?Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?
www.zacks.com - January 17 at 4:35 PM
Form 6-K NOVO NORDISK AS For: Jan 15 - StreetInsider.comForm 6-K NOVO NORDISK AS For: Jan 15 - StreetInsider.com
www.streetinsider.com - January 17 at 10:18 AM
Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?
finance.yahoo.com - January 17 at 10:18 AM
Eli Lillys Risks Could Be Underappreciated, Goldman Sachs Says In DowngradeEli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade
finance.yahoo.com - January 16 at 4:32 PM
Three Diabetes Clinical Trials to Watch in 2018Three Diabetes Clinical Trials to Watch in 2018
finance.yahoo.com - January 12 at 4:26 PM
How Is Bioverativ’s Eloctate Positioned Now?How Is Bioverativ’s Eloctate Positioned Now?
finance.yahoo.com - January 11 at 10:47 AM
Ablynx NV (ABLX) Says Novo Nordisk (NVO) Offer Undervalues Company - StreetInsider.comAblynx NV (ABLX) Says Novo Nordisk (NVO) Offer Undervalues Company - StreetInsider.com
www.streetinsider.com - January 10 at 4:33 PM
Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to KnowEli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
finance.yahoo.com - January 10 at 4:33 PM
Novo Nordisk's Ozempic Gets Canadian Approval for DiabetesNovo Nordisk's Ozempic Gets Canadian Approval for Diabetes
finance.yahoo.com - January 10 at 10:27 AM
Novo Nordisk Confirms Bid for Ablynx But Faces RejectionNovo Nordisk Confirms Bid for Ablynx But Faces Rejection
www.zacks.com - January 9 at 10:17 AM
Ozempic® approved in Canada for the treatment of adults with type 2 diabetesOzempic® approved in Canada for the treatment of adults with type 2 diabetes
finance.yahoo.com - January 9 at 10:16 AM
A Peek Into The Markets: US Stock Futures Mostly Flat Ahead Of Fed Speakers - BenzingaA Peek Into The Markets: US Stock Futures Mostly Flat Ahead Of Fed Speakers - Benzinga
www.benzinga.com - January 8 at 4:39 PM
ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK ... - NasdaqABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK ... - Nasdaq
www.nasdaq.com - January 8 at 4:39 PM
Novo Nordisk A/S: Share repurchase programme - GlobeNewswire (press release)Novo Nordisk A/S: Share repurchase programme - GlobeNewswire (press release)
globenewswire.com - January 8 at 4:39 PM
Novo Goes Public With $3.1 Billion Bid to Pressure AblynxNovo Goes Public With $3.1 Billion Bid to Pressure Ablynx
finance.yahoo.com - January 8 at 10:33 AM
In Drug Deals, $3.1 Billion Isnt Exactly Full-BloodedIn Drug Deals, $3.1 Billion Isn't Exactly Full-Blooded
finance.yahoo.com - January 8 at 10:33 AM
Novo Nordisk submits proposal to buy biopharmaceutical fi...Novo Nordisk submits proposal to buy biopharmaceutical fi...
finance.yahoo.com - January 8 at 10:33 AM
[$$] Belgiums Ablynx Rejects Novo Nordisk Bid[$$] Belgium's Ablynx Rejects Novo Nordisk Bid
finance.yahoo.com - January 8 at 10:33 AM
Ablynx shares soar after rejects Novo Nordisks $3.1 bln bidAblynx shares soar after rejects Novo Nordisk's $3.1 bln bid
finance.yahoo.com - January 8 at 10:33 AM
How Novo Nordisk Performed in 3Q17How Novo Nordisk Performed in 3Q17
finance.yahoo.com - January 4 at 4:34 PM
Can Merck Regain its Mojo in 2018 After an Unimpressive '17?Can Merck Regain its Mojo in 2018 After an Unimpressive '17?
finance.yahoo.com - January 3 at 4:35 PM
Form 6-K NOVO NORDISK AS For: Jan 02 - StreetInsider.comForm 6-K NOVO NORDISK AS For: Jan 02 - StreetInsider.com
www.streetinsider.com - January 2 at 5:24 PM
Novo Nordisk A/S: Status regarding Novo Nordisks holding of its own shares (31 December 2017) - GlobeNewswire (press release)Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 December 2017) - GlobeNewswire (press release)
globenewswire.com - January 2 at 5:24 PM
Novo Nordisk A/S (NVO) Stock Rating Upgraded by Zacks Investment ResearchNovo Nordisk A/S (NVO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:00 PM
Novo Nordisk A/S: Status regarding Novo Nordisks holding of its own shares (31 December 2017)Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 December 2017)
finance.yahoo.com - January 2 at 10:14 AM
Novo Nordisk A/S (NVO) Given Average Rating of "Hold" by BrokeragesNovo Nordisk A/S (NVO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 29 at 8:04 AM
Novo Nordisk A/S (NVO) Upgraded to Hold by JPMorgan Chase & Co.Novo Nordisk A/S (NVO) Upgraded to Hold by JPMorgan Chase & Co.
www.americanbankingnews.com - December 29 at 7:20 AM
Form 6-K NOVO NORDISK AS For: Dec 27 - StreetInsider.comForm 6-K NOVO NORDISK AS For: Dec 27 - StreetInsider.com
www.streetinsider.com - December 27 at 12:40 PM
3 Top Pharmaceutical Dividend Stocks to Buy Now3 Top Pharmaceutical Dividend Stocks to Buy Now
finance.yahoo.com - December 27 at 12:40 PM
Notable ETF Inflow Detected - VIGI, NVO, UN, WBKNotable ETF Inflow Detected - VIGI, NVO, UN, WBK
www.nasdaq.com - December 26 at 3:40 PM
This Mornings Technical Outlook on Drug Makers Stocks -- Synergy Pharma, Depomed, United Therapeutics, and ... - PR Newswire (press release)This Morning's Technical Outlook on Drug Makers Stocks -- Synergy Pharma, Depomed, United Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - December 20 at 10:26 AM
ETFs with exposure to Novo Nordisk A/S : December 14, 2017ETFs with exposure to Novo Nordisk A/S : December 14, 2017
finance.yahoo.com - December 14 at 5:04 PM
Novo Nordisk: An Update Based On Recent Newsflow - Seeking Alpha - Seeking AlphaNovo Nordisk: An Update Based On Recent Newsflow - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 9 at 4:29 PM
Quant Score Keeps Novo Nordisk A/S (NVO) Shares a Buy - Investorplace.comQuant Score Keeps Novo Nordisk A/S (NVO) Shares a Buy - Investorplace.com
investorplace.com - December 9 at 10:23 AM
Investors Purchase High Volume of Put Options on Novo Nordisk A/S (NVO)Investors Purchase High Volume of Put Options on Novo Nordisk A/S (NVO)
www.americanbankingnews.com - December 7 at 1:10 AM
Novo Nordisk A/S (NVO) Lifted to Buy at Bank of AmericaNovo Nordisk A/S (NVO) Lifted to Buy at Bank of America
www.americanbankingnews.com - December 6 at 9:20 PM
Novo Nordisk's Semaglutide Gets FDA Approval for DiabetesNovo Nordisk's Semaglutide Gets FDA Approval for Diabetes
finance.yahoo.com - December 6 at 10:40 AM
Sanofi's Toujeo Meets Key Objective in Head-to-Head StudySanofi's Toujeo Meets Key Objective in Head-to-Head Study
finance.yahoo.com - December 5 at 12:03 PM
Novo Nordisk A/S (NVO) Receives Consensus Recommendation of "Hold" from BrokeragesNovo Nordisk A/S (NVO) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 4 at 8:44 AM
Novo Nordisk A/S (NVO) Stock Rating Upgraded by Morgan StanleyNovo Nordisk A/S (NVO) Stock Rating Upgraded by Morgan Stanley
www.americanbankingnews.com - December 1 at 10:34 PM
High-Level Quant Score Keeps Novo Nordisk A/S (NVO) a Strong Buy - Investorplace.comHigh-Level Quant Score Keeps Novo Nordisk A/S (NVO) a Strong Buy - Investorplace.com
investorplace.com - November 25 at 5:13 PM
High-Level Quant Score Keeps Novo Nordisk A/S (NVO) a Strong BuyHigh-Level Quant Score Keeps Novo Nordisk A/S (NVO) a Strong Buy
investorplace.com - November 24 at 11:28 AM
Health Canada approves Victoza® as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.Health Canada approves Victoza® as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.
finance.yahoo.com - November 21 at 8:52 AM
Novo Nordisk: Q3 2017 Results Show Strong Future Potential - Seeking AlphaNovo Nordisk: Q3 2017 Results Show Strong Future Potential - Seeking Alpha
seekingalpha.com - November 18 at 9:23 AM
Novo Nordisk A/S (NVO) a Strong Buy on High-Level Earnings Momentum - Investorplace.comNovo Nordisk A/S (NVO) a Strong Buy on High-Level Earnings Momentum - Investorplace.com
investorplace.com - November 18 at 9:23 AM

SEC Filings

Novo Nordisk A/S (NYSE:NVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novo Nordisk A/S (NYSE:NVO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novo Nordisk A/S (NYSE NVO) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.